NYSE: JNJJohnson & Johnson Stock
$168.23-0.66 (-0.39%)
Updated Jan 27, 2023
JNJ Price
$168.23
Fair Value Price
N/A
Market Cap
$439.83B
52 Week Low
$155.72
52 Week High
$186.69
P/E
23.05x
P/B
5.9x
P/S
4.47x
PEG
1.46x
Dividend Yield
2.65%
Revenue
$96.04B
Earnings
$19.16B
Gross Margin
67.4%
Operating Margin
23.45%
Profit Margin
19.9%
Debt to Equity
1.35
Operating Cash Flow
$22B
Beta
0.56
Next Earnings
N/A
Ex-Dividend
Feb 17, 2023
Next Dividend
Mar 7, 2023
JNJ Overview
Johnson & Johnson manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases. Other offerings include oral care, baby care, beauty, over-the-counter pharmaceutical, women's health, and wound care products, as well as medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. It distributes its products to retailers, wholesalers, health care professionals, and hospitals. J&J was founded in 1886 and is headquartered in New Brunswick, NJ.
Zen Score
–
Industry Average (44)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how JNJ scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
JNJ ($168.23) is trading above its intrinsic value of $85.45, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
JNJ is good value based on its earnings relative to its share price (23.05x), compared to the US market average (23.59x)
P/E vs Market Valuation
JNJ is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more JNJ due diligence checks available for Premium users.
Be the first to know about important JNJ news, forecast changes, insider trades & much more!
JNJ News
Valuation
JNJ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
23.05x
Industry
30.12x
Market
23.59x
JNJ is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
JNJ is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
JNJ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.9x
Industry
5.24x
JNJ is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
JNJ price to earnings growth (PEG)
For valuing profitable companies with growth potential
JNJ is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
JNJ's financial health
Profit margin
Revenue
$23.8B
Net Income
$4.5B
Profit Margin
18.7%
JNJ's Earnings (EBIT) of $22.52B... subscribe to Premium to read more.
Interest Coverage Financials
JNJ's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$175.1B
Liabilities
$100.5B
Debt to equity
1.35
JNJ's short-term assets ($65.24B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
JNJ's short-term assets ($65.24B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
JNJ's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
JNJ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$6.3B
Investing
-$1.7B
Financing
-$3.9B
JNJ's operating cash flow ($21.58B)... subscribe to Premium to read more.
Debt Coverage Financials
JNJ vs General Drug Manufacturer Stocks
Johnson & Johnson Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.